Breaking Down Doctorglasses Chain Co.,Ltd. Financial Health: Key Insights for Investors

Curious whether Doctorglasses Chain Co., Ltd. (300622.SZ) is a resilient bet or a risky play? The numbers tell a vivid story: trailing twelve-month revenue through June 2025 reached CNY 1.274 billion (up 9.37% year-over-year) following 2024 revenue of CNY 1.20 billion, with a 2024 sales mix of 67% from optical glasses and fitting services, 14.8% from Chengjing and 13% from contact lenses; direct stores generated 78.49% of sales while online accounted for 14.12%. Profitability shows moderate momentum-TTM net profit attributable to shareholders was CNY 87.83 million (up 5.21%), TTM EPS was CNY 0.39, ROE 13.25%, operating margin 10.27% and EBITDA margin 10.49%, even as 2024 gross margin eased to 61.7% (-1.36 pp) and net margin to 8.42% (-1.97 pp). The balance sheet and liquidity read strongly: debt-to-equity was 0.24 with total debt CNY 203.44 million vs. equity CNY 860.93 million, interest coverage 18.47, current ratio 2.57, quick ratio 1.53, net cash CNY 258.45 million and operating cash flow of CNY 327.86 million with free cash flow CNY 306.75 million and cash & equivalents CNY 461.89 million; Altman Z-Score stood at 12.2. Valuation metrics as of Nov 28, 2025 show a TTM P/E of 66.27, forward P/E 51.97, P/S 5.23, P/B 8.31, EV/EBITDA 25.87 and EV/FCF 22.51. Key risks include fierce fragmentation in China's optical retail market, capital intensity of store networks and regional concentration in Southern China, while growth levers feature 100+ stores with smart-glasses counters, AR partnerships, a new eco-friendly eyewear line forecasted to add CNY 5 million in the first two years, and freshly established Data and User Operation departments-read on for a chapter-by-chapter breakdown of what these figures mean for investors.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Revenue Analysis

• Operating revenue (TTM ending June 2025): CNY 1.274 billion - a 9.37% increase from the prior 12-month period (implied prior-period TTM: CNY 1.165 billion).
• Full-year 2024 revenue: CNY 1.200 billion - a 2.29% YoY increase from 2023 (2023 revenue: CNY 1.173 billion, based on reversal of the 2.29% growth).
• Revenue composition (2024):
  • Optical glasses and fitting services: 67.0%
  • Chengjing: 14.8%
  • Contact lenses: 13.0%
• Channel mix (2024): direct store revenue 78.49% of total; online transactions 14.12% of total.
• Profitability (2024): gross profit margin 61.7% (down 1.36 percentage points vs. 2023); net profit margin 8.42% (down 1.97 percentage points vs. 2023).

• Key structural takeaways:
  • Core revenue concentration in optical glasses and fitting services (67% of 2024 revenue) drives recurring store-based sales.
  • High direct-store dependency (78.49%) leaves the company exposed to offline footfall and regional retail dynamics; online remains a smaller but growing channel (14.12%).
  • Margins remain robust (gross margin >60%), but slight margin compression in 2024 and reduced net margin (8.42%) signal cost or pricing pressure that investors should monitor.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Profitability Metrics

• Net profit attributable to shareholders (TTM Jun 2025): CNY 87.83 million (+5.21% YoY)
• Net profit margin (TTM Jun 2025): 7.89%
• Basic EPS (TTM Jun 2025): CNY 0.39
• Return on equity (ROE, TTM Jun 2025): 13.25%
• Operating margin (TTM Jun 2025): 10.27%
• EBITDA margin (TTM Jun 2025): 10.49%

• Margins clustered around ~10% indicate consistent operational conversion of revenue into profit and cash-flow proxies.
• ROE of 13.25% suggests the company is delivering mid-teens returns on equity - attractive relative to many peers in the retail/optical services space.
• EPS of CNY 0.39 combined with modest net profit growth (+5.21%) signals steady, not explosive, earnings expansion.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.24 (June 2025)
• Total debt: CNY 203.44 million (June 2025)
• Total equity: CNY 860.93 million (June 2025)
• Interest coverage (TTM to June 2025): 18.47
• Current ratio: 2.57 (June 2025)
• Quick ratio: 1.53 (June 2025)
• Net cash position: CNY 258.45 million (June 2025)

• Implication for investors: balance-sheet resilience and lower financial risk compared with higher-leverage peers.
• Potential uses of net cash: working capital, selective M&A, store expansion, or shareholder returns.
• Watch factors: changes in earnings that could affect interest coverage and any material rise in gross debt.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Liquidity and Solvency

• Operating cash flow (TTM ending June 2025): CNY 327.86 million
• Free cash flow (TTM ending June 2025): CNY 306.75 million
• Cash & cash equivalents (as of June 2025): CNY 461.89 million
• Net cash per share (as of June 2025): CNY 1.13
• Working capital (as of June 2025): CNY 624.56 million
• Altman Z-Score: 12.2 (low distress risk)

• Short-term coverage: strong given cash balance and positive operating cash flow; current working capital provides a buffer versus near-term liabilities.
• Solvency outlook: robust - high Altman Z-Score (12.2) and net cash per share support long-term creditor confidence.
• Capital allocation flexibility: FCF of CNY 306.75M enables potential share buybacks, dividend policy support, or debt reduction without compromising operations.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Valuation Analysis

• High TTM P/E (66.27 on 2025-11-28) versus forward P/E (51.97) suggests analysts expect earnings growth, yet current shares remain richly priced.
• Elevated P/S (5.23) and P/B (8.31) point to strong revenue and asset valuation premia, likely driven by brand, store economics, or differentiated products/services.
• EV/EBITDA (25.87) and EV/FCF (22.51) indicate investors are paying up for both operating performance and free cash generation; this compresses margin for error if growth slows.

• Key investor considerations:
  • Growth vs. valuation trade-off - assess forecast visibility and execution risks.
  • Compare these multiples to domestic retail/healthcare retail peers for relative attractiveness.
  • Monitor upcoming earnings, same-store sales, margin trends, and capex-to-FCF conversion.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Risk Factors

• Highly fragmented competitive landscape: international brands (e.g., EssilorLuxottica), national chains and numerous local independents increase pricing and marketing pressure.
• Capital intensity of store network: ongoing investment in new openings, refurbishments and inventory (lenses, frames, equipment) can compress free cash flow.
• Margin pressure from rising operating costs: rents, labor, raw materials (acetate/metal frames, lens materials) and logistics can erode gross and operating margins.
• Consumer discretionary volatility: eyewear demand is correlated with discretionary spending and reimbursement trends for vision care.
• Regional concentration risk: heavy exposure to Southern China limits the company's buffer against localized economic downturns.
• Regulatory and compliance risk: evolving retail, health product and e-commerce rules in China could raise compliance costs or restrict sales channels.

• Rising rents or labor costs: a 200-300 bp decline in operating margin could reduce annual net income by ~25-35% based on current cost structure.
• Slower discretionary spend: a 4-6% revenue contraction would magnify fixed-cost leverage from the physical store base, pressuring cash flow and requiring higher working capital.
• Inventory obsolescence risk: fashion trends and prescription mix shifts can increase markdowns and shrink gross margin seasonally.
• Expansion capital needs: targeted geographic diversification beyond Southern China would likely require incremental capex and working capital, increasing leverage if funded with debt.
• Regulatory shocks: stricter controls on medical device classification, online prescription verification or promotional practices could restrict e-commerce growth or increase compliance spend.

Doctorglasses Chain Co.,Ltd. (300622.SZ) - Growth Opportunities

• Smart glasses retail rollout: the company reports over 100 retail stores currently featuring dedicated smart-glasses counters; management targets 250 counters within 18 months, implying a 150% expansion in smart-glasses retail presence.
• Tech partnerships: collaborations with leading AR/optics firms aim to enable virtual try-on features that can increase conversion rates by an estimated 3-5 percentage points in participating stores and online channels.
• Eco-friendly product line: launch expected to contribute approximately CNY 5 million in incremental revenue within the first two years, with gross margins projected near 30% (higher than core assortments by ~3-5 percentage points due to premium positioning).
• Digital organization buildout: establishment of a Data Operation Department and a User Operation Department to support personalization, CRM-driven upsell, and retention programs - modeled to lift same-store digital sales penetration from current levels toward a 20-25% target over two years.
• Direct store network expansion and channel optimization: continued addition of self-operated stores and optimization of product/channel mix expected to improve store-level EBITDA through higher traffic and SKU rationalization.

• Near-term KPI targets: 250 smart counters, CNY 5m eco-line contribution (2 years), digital penetration 22% (24 months), AR try-on conversion uplift 4-5% in mature locations.
• Financial sensitivities: a 1 percentage-point higher digital conversion can translate to CNY 8-12m additional annual revenue; each 10% increase in smart-glasses ASP can add CNY 4-6m to gross profit annually under current volumes.